Concord Medical Services (CCM) AI Stock Analysis

• Market Cap: $27.03M
• Dividend Yield: N/A
• Average Volume (3M): 2.48K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.09
• Revenue Growth: -29.82%
• EPS Growth: -2.57%
• Country: US
• Employees: 595
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -9.83
• Shares Outstanding: 2,815,458
• 10 Day Avg. Volume: 2,552
• 30 Day Avg. Volume: 2,478
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 38.64
• Enterprise Value/Revenue: 2.21
• Enterprise Value/Gross Profit: -12.93
• Enterprise Value/Ebitda: -3.20
• 1Y Price Target: $6.00
• Price Target Upside: -3.54% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: $6.00 ▼(-3.54% Downside)

The overall stock score is heavily influenced by Concord Medical Services' poor financial performance, which is the most significant factor. While technical analysis shows some positive signs, the negative valuation metrics further weigh down the score.

Concord Medical Services Business Overview & Revenue Model

Company Description

Concord Medical Services Holdings Limited, together its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company operates in two segments, Network and Hospital. Its services include linear accelerators external beam radiotherapy, gamma knife radiosurgery, head gamma knife systems, body gamma knife systems, and diagnostic imaging services. The company's other treatments and diagnostic services comprise computed tomography scanners. In addition, it provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, the company offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, it operates specialty cancer hospitals, which offer radiotherapy services, diagnostic imaging services, chemotherapy, and surgery. As of December 31, 2021, it operated a network of 16 cooperative centers based in 13 hospitals. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.

How the Company Makes Money

Concord Medical Services generates revenue primarily through the provision of radiotherapy services to cancer patients. The company earns income from patient treatment fees, which include charges for the use of advanced medical equipment and facilities. Additionally, CCM has established several key partnerships with medical device manufacturers, allowing it to lease cutting-edge technology and equipment to its centers, further contributing to its revenue stream. The leasing agreements and technical service contracts also provide a consistent source of income, while collaborations with government healthcare programs and hospitals enhance the company’s market presence and patient referral base.

Concord Medical Services Financial Statement Overview

Summary

Concord Medical Services is experiencing severe financial difficulties. The income statement shows a significant revenue decline and negative profit margins. The balance sheet indicates high leverage and solvency issues, with liabilities exceeding assets. Cash flows are negative, highlighting unsustainable reliance on external financing.

Income Statement

Concord Medical Services has experienced a persistent decline in revenue with a sharp drop from $537M in 2023 to $384M in 2024. Negative gross profit and EBIT margins indicate significant operational challenges. The net profit margin remains deeply negative, reflecting ongoing financial struggles.

Balance Sheet

The company's balance sheet shows considerable financial distress, with negative stockholders' equity reflecting a heavily leveraged position. The debt-to-equity ratio is not calculable due to negative equity, signaling high risk. Total liabilities exceed assets, indicating solvency issues.

Cash Flow

Cash flows are under pressure, with consistently negative operating and free cash flows. Despite a growth in financing cash flow, the reliance on external financing is unsustainable given the weak free cash flow to net income ratio, which remains negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	471.70M	383.96M	537.40M	472.08M	485.63M	223.01M
Gross Profit	-80.78M	-79.16M	-76.61M	-152.41M	-56.90M	13.08M
EBITDA	-326.79M	-345.62M	-344.16M	-401.86M	-363.86M	-236.72M
Net Income	-378.93M	-308.24M	-297.66M	-489.66M	-271.43M	-309.99M
Balance Sheet
Total Assets	6.62B	6.73B	6.05B	6.00B	6.23B	5.33B
Cash, Cash Equivalents and Short-Term Investments	326.90M	350.85M	58.14M	158.28M	157.39M	334.26M
Total Debt	3.56B	3.93B	3.30B	3.24B	2.73B	2.35B
Total Liabilities	4.70B	5.11B	4.31B	3.99B	3.49B	2.93B
Stockholders Equity	-2.14B	-2.28B	-2.12B	-1.86B	-1.37B	-662.96M
Cash Flow
Free Cash Flow	0.00	-808.58M	-392.17M	-600.47M	-1.12B	-734.47M
Operating Cash Flow	0.00	-397.75M	-276.47M	-216.69M	-359.31M	-229.77M
Investing Cash Flow	0.00	-593.44M	-47.68M	-118.79M	-565.98M	-533.88M
Financing Cash Flow	0.00	1.15B	257.65M	383.09M	642.45M	1.14B

Concord Medical Services Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.22
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCM, the sentiment is Positive. The current price of 6.22 is above the 20-day moving average (MA) of 5.68, above the 50-day MA of 5.49, and above the 200-day MA of 5.44, indicating a bullish trend. The MACD of 0.22 indicates Negative momentum. The RSI at 57.93 is Neutral, neither overbought nor oversold. The STOCH value of 86.82 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CCM.

Concord Medical Services Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMS	57 Neutral	18.88M	-7.85	-9.97%	―	26.61%	-156.30%
CCEL	50 Neutral	38.67M	-205.13	1.10%	8.33%	1.10%	98.13%
PIII	48 Neutral	70.15M	-0.20	-178.90%	―	4.20%	-54.16%
CCM	46 Neutral	$27.03M	―	14.03%	―	-29.82%	-2.57%
TOI	45 Neutral	331.01M	-5.23	733.32%	―	17.53%	14.49%
MODVQ	40 Underperform	2.56M	-0.01	523.15%	―	-0.70%	-2.38%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Concord Medical Services Corporate Events

Concord Healthcare Releases Interim Results for H1 2025

Concord Healthcare, a subsidiary of Concord Medical Services Holdings Limited, announced its interim results for the first half of 2025 on August 28, 2025. The announcement follows the listing of Concord Healthcare’s H shares on the Hong Kong Stock Exchange in January 2024, indicating a strategic move to enhance its market presence and financial transparency.

Concord Healthcare Completes Share Placement Under General Mandate

On July 29, 2025, Concord Healthcare Group Co., Ltd., a subsidiary of Concord Medical Services, successfully completed the placement of 48,723,600 new shares under a general mandate. The shares were placed at a price of HK$5.54 each to no fewer than six placees, marking a significant step in the company’s financial strategy and potentially strengthening its market position.

Concord Healthcare Announces New Share Placement

On July 22, 2025, Concord Healthcare, a subsidiary of Concord Medical Services Holdings Limited, announced a placing agreement with Guotai Junan Securities (Hong Kong) Limited. This agreement involves the placement of 48,723,600 new shares at a price of HK$5.54 per share, aimed at independent third-party investors. This move is part of Concord Healthcare’s strategic efforts to strengthen its financial position following its listing on the Hong Kong Stock Exchange in January 2024.

Concord Medical Services Achieves Milestone with First Proton Therapy for Eye Cancer in China

On July 11, 2025, Concord Healthcare, a subsidiary of Concord Medical Services, successfully completed China’s first proton therapy treatment for choroidal malignant melanoma at the Guangzhou Concord Cancer Center. This innovative treatment offers a new eye-preserving option for patients, avoiding the traditional method of enucleation, and marks a significant advancement in oncology care within China.

Concord Medical Services Enhances 2024 Annual Report with Proton Therapy Details

On July 7, 2025, Concord Medical Services Holdings Limited announced a supplemental announcement regarding its 2024 annual report, specifically providing additional information on proton therapy services. This follows the listing of its subsidiary, Concord Healthcare Group Co., Ltd., on the Hong Kong Stock Exchange on January 9, 2024, which marks a significant step in enhancing its market presence and accessibility to investors.

Concord Medical Services Announces Changes in Controlling Shareholders

Concord Medical Services Holdings Limited announced changes in the controlling shareholders of its subsidiary, Concord Healthcare Group Co., Ltd., which is listed on the Hong Kong Stock Exchange. This announcement follows the previous listing of Concord Healthcare’s H shares on the HKSE on January 9, 2024, and may impact the company’s market positioning and stakeholder interests.

Concord Healthcare Announces Shareholding Change by Major Shareholder

On June 20, 2025, Concord Healthcare Group Co., Ltd., a subsidiary of Concord Medical Services, announced that its controlling shareholder, Beijing Concord Medical Technology Co., Ltd., sold 32,800,000 H shares of Concord Healthcare. This transaction, conducted at HK$6.12 per share, represents approximately 4.46% of the total issued shares, impacting the company’s shareholding structure.